Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Human regulatory proteins associate with non-coding RNAs from the EBV IR1 region.

Tompkins VS, Valverde DP, Moss WN.

BMC Res Notes. 2018 Feb 20;11(1):139. doi: 10.1186/s13104-018-3250-8.

2.

Preclinical activity of DCZ3301, a novel aryl-guanidino compound in the therapy of multiple myeloma.

Gao M, Li B, Sun X, Zhou Y, Wang Y, Tompkins VS, Xu Z, Indima N, Wang H, Xiao W, Gao L, Chen G, Wu H, Wu X, Kong Y, Xie B, Zhang Y, Chang G, Hu L, Yang G, Dai B, Tao Y, Zhu W, Shi J.

Theranostics. 2017 Aug 23;7(15):3690-3699. doi: 10.7150/thno.18345. eCollection 2017.

3.

Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia.

Tompkins VS, Sompallae R, Rosean TR, Walsh S, Acevedo M, Kovalchuk AL, Han SS, Jing X, Holman C, Rehg JE, Herms S, Sunderland JS, Morse HC, Janz S.

Blood Cancer J. 2016 Nov 4;6(11):e488. doi: 10.1038/bcj.2016.95.

4.

PIAS1 Promotes Lymphomagenesis through MYC Upregulation.

Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP.

Cell Rep. 2016 Jun 7;15(10):2266-2278. doi: 10.1016/j.celrep.2016.05.015. Epub 2016 May 26.

5.

KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice.

Rosean TR, Holman CJ, Tompkins VS, Jing X, Krasowski MD, Rose-John S, Janz S.

Blood Cancer J. 2016 Feb 26;6:e398. doi: 10.1038/bcj.2016.6. No abstract available.

6.

FOXM1 is a therapeutic target for high-risk multiple myeloma.

Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S.

Leukemia. 2016 Apr;30(4):873-82. doi: 10.1038/leu.2015.334. Epub 2015 Dec 9.

7.

Adoptive B-cell transfer mouse model of human myeloma.

Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, Duncan KM, Jing X, Foor SD, Acevedo MR, Walsh SA, Tricot G, Zhan F, Janz S.

Leukemia. 2016 Apr;30(4):962-6. doi: 10.1038/leu.2015.197. Epub 2015 Jul 23. No abstract available.

8.

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.

Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S.

Exp Hematol Oncol. 2015 Mar 27;4:9. doi: 10.1186/s40164-015-0005-2. eCollection 2015.

9.

NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas.

Reed SM, Hagen J, Muniz VP, Rosean TR, Borcherding N, Sciegienka S, Goeken JA, Naumann PW, Zhang W, Tompkins VS, Janz S, Meyerholz DK, Quelle DE.

PLoS One. 2014 Nov 13;9(11):e112126. doi: 10.1371/journal.pone.0112126. eCollection 2014.

10.

Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized, controlled trials.

Gao M, Yang G, Tompkins VS, Gao L, Wu X, Tao Y, Hu X, Hou J, Han Y, Xu H, Zhan F, Shi J.

PLoS One. 2014 Oct 3;9(10):e109758. doi: 10.1371/journal.pone.0109758. eCollection 2014.

11.

The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.

Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC 3rd, Waldschmidt TJ, Janz S.

Leukemia. 2015 Jan;29(1):233-7. doi: 10.1038/leu.2014.260. Epub 2014 Sep 3. No abstract available.

12.

Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells.

Eckers JC, Kalen AL, Sarsour EH, Tompkins VS, Janz S, Son JM, Doskey CM, Buettner GR, Goswami PC.

Radiat Res. 2014 Oct;182(4):420-9. doi: 10.1667/RR13726.1. Epub 2014 Sep 17.

13.

Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.

Gao M, Gao L, Yang G, Tao Y, Tompkins VS, Wu X, Xu H, Zhan F, Shi J.

Int J Clin Exp Pathol. 2014 May 15;7(6):3073-80. eCollection 2014.

14.

Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma.

Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S.

Immunol Res. 2014 Aug;59(1-3):188-202. doi: 10.1007/s12026-014-8528-x. Review.

15.

Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells.

Gao M, Gao L, Tao Y, Hou J, Yang G, Wu X, Xu H, Tompkins VS, Han Y, Wu H, Zhan F, Shi J.

Acta Biochim Biophys Sin (Shanghai). 2014 Jun;46(6):484-91. doi: 10.1093/abbs/gmu030. Epub 2014 May 6.

PMID:
24801128
16.

Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53.

Reed SM, Hagen J, Tompkins VS, Thies K, Quelle FW, Quelle DE.

Cell Cycle. 2014;13(8):1288-98. doi: 10.4161/cc.28202. Epub 2014 Feb 19.

17.

(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.

Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S.

Blood Cancer J. 2013 Nov 29;3:e165. doi: 10.1038/bcj.2013.61.

18.

RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts.

Zhang X, Hagen J, Muniz VP, Smith T, Coombs GS, Eischen CM, Mackie DI, Roman DL, Van Rheeden R, Darbro B, Tompkins VS, Quelle DE.

PLoS One. 2013 Nov 25;8(11):e80228. doi: 10.1371/journal.pone.0080228. eCollection 2013.

19.

RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.

Muniz VP, Askeland RW, Zhang X, Reed SM, Tompkins VS, Hagen J, McDowell BD, Button A, Smith BJ, Weydert JA, Mezhir JJ, Quelle DE.

Genes Cancer. 2013 Jul;4(7-8):273-84. doi: 10.1177/1947601913501074.

20.

Identification of candidate B-lymphoma genes by cross-species gene expression profiling.

Tompkins VS, Han SS, Olivier A, Syrbu S, Bair T, Button A, Jacobus L, Wang Z, Lifton S, Raychaudhuri P, Morse HC 3rd, Weiner G, Link B, Smith BJ, Janz S.

PLoS One. 2013 Oct 9;8(10):e76889. doi: 10.1371/journal.pone.0076889. eCollection 2013.

21.

Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells.

Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S.

Biochem Biophys Res Commun. 2013 Jul 12;436(4):660-5. doi: 10.1016/j.bbrc.2013.06.012. Epub 2013 Jun 11.

22.

HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice.

Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S.

Blood. 2012 May 31;119(22):5173-81. doi: 10.1182/blood-2011-09-377705. Epub 2012 Apr 9.

23.

NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.

Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S.

Mol Cancer. 2010 Apr 30;9:97. doi: 10.1186/1476-4598-9-97.

24.

Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism.

Kinney EL, Tanida S, Rodrigue AA, Johnson JK, Tompkins VS, Sakamuro D.

J Cell Physiol. 2008 Sep;216(3):621-31. doi: 10.1002/jcp.21437.

PMID:
18348166
25.

A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability.

Tompkins VS, Hagen J, Frazier AA, Lushnikova T, Fitzgerald MP, di Tommaso A, Ladeveze V, Domann FE, Eischen CM, Quelle DE.

J Biol Chem. 2007 Jan 12;282(2):1322-33. Epub 2006 Nov 16.

Supplemental Content

Loading ...
Support Center